Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

DISEASE CHARACTERISTICS: Diagnosis of 1 of the following hematologic malignancies: Stage II or III multiple myeloma Amyloidosis Myelofibrosis with ≥ 2 of the following high-risk features: Over 55 years of age Hemoglobin < 10 g/dL WBC < 3,000/mm^3 OR > 10,000/mm^3 Platelet count < 100,000/mm^3 Cytogenetic abnormalities Mycosis fungoides, meeting 1 of the following criteria: Stage IIB or III disease with evidence of histologic conversion to an aggressive lymphoma Must demonstrate chemosensitivity Stage IV disease Paroxysmal nocturnal hemoglobinuria Not meeting criteria for other bone marrow transplantation (BMT) or treatment studies Diagnosis of 1 of the following hematologic malignancies, for which patient is not eligible for potentially curative allogeneic BMT due to end-organ dysfunction, age 65 to 75, or the amount of prior chemotherapy: Acute myeloid or acute lymphoblastic leukemia High-risk disease in first or second (or further) complete remission Relapsed aggressive non-Hodgkin's lymphoma Not eligible for autologous or standard allogeneic BMT Hodgkin's lymphoma in second or further complete or partial remission Not eligible for autologous or standard allogeneic BMT Myelodysplastic syndromes or myelodysplastic/myeloproliferative diseases Any of the following subtypes: Refractory anemia with excess blasts (RAEB) RAEB in transformation Chronic myelomonocytic leukemia Any morphologic subtype with multiple chromosomal abnormalities Any subset with life-threatening cytopenias in all 3 cell lines, defined as platelet count ≤ 20,000/mm^3, absolute neutrophil count ≤ 500/mm^3, and reticulocyte count ≤ 50,000/mm^3 Meets both of the following criteria: Less than 20% blasts by bone marrow biopsy Not eligible for standard allogeneic BMT No refractory anemia with ringed sideroblasts No 5q syndrome Stage III or IV chronic lymphocytic leukemia Not meeting criteria for other BMT studies Chronic myelogenous leukemia in first or second chronic phase Not meeting criteria for other BMT studies or treatment Stage III or IV indolent small lymphocytic or follicular lymphoma Not eligible for autologous or standard allogeneic BMT or other active protocols at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Must have an HLA-identical related donor available PATIENT CHARACTERISTICS: Performance status ECOG 0-2 Life expectancy Not specified Hematopoietic See Disease Characteristics Hepatic Bilirubin ≤ 3.0 mg/dL AST ≤ 175 U/L ALT ≤ 200 U/L Renal Creatinine ≤ 3.0 mg/dL Cardiovascular LVEF ≥ 30% Pulmonary FEV_1 ≥ 40% predicted Forced vital capacity ≥ 40% predicted Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception HIV negative PRIOR CONCURRENT THERAPY: Chemotherapy See Disease Characteristics